Analyst Price Targets — DRIO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 14, 2025 12:45 pm | — | Stifel Nicolaus | $16.00 | $10.61 | StreetInsider | DarioHealth Corp. (DRIO) PT Raised to $16 at Stifel Following 20-1 Stock Split |
| November 16, 2022 8:28 am | — | Industrial Alliance Securities | $7.50 | $5.18 | Benzinga | Alliance Global Partners Maintains Buy on DarioHealth, Lowers Price Target to $7.5 |
| August 18, 2022 1:37 am | — | Cowen & Co. | $14.00 | $5.49 | Benzinga | Cowen & Co. Maintains Outperform on DarioHealth, Lowers Price Target to $14 |
| May 16, 2022 8:56 am | — | Cowen & Co. | $18.00 | $6.33 | Benzinga | Cowen & Co. Maintains Outperform on DarioHealth, Raises Price Target to $18 |
Latest News for DRIO
Findings highlight the role of continuous behavioral support in improving focus, productivity and day-to-day functioning – key priorities for employers and health plans Statistically significant improvements in workplace functioning highlight the potential economic value of Dario's digital health solutions for payers NEW YORK, April 20, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company",…
Mr. Palumbo's deep relationships across health systems, payers and healthcare's senior executive community expected to accelerate Dario's commercial partnerships and position the Company to realize its full strategic value NEW YORK, April 13, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company" or "Dario"), a leader in global digital health, today announced the appointment of John R. Palumbo to its…
DarioHealth (NASDAQ: DRIO - Get Free Report) and Thermo Fisher Scientific (NYSE: TMO - Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings and analyst recommendations. Insider and Institutional Ownership 33.4% of DarioHealth shares
DarioHealth (NASDAQ: DRIO) executives highlighted record commercial momentum and continued cost reductions on the company's fourth-quarter and year-end 2025 earnings call, while also addressing the revenue impact of a single legacy customer non-renewal and outlining expectations for accelerating growth through 2026. Record new agreements, but full-year revenue declined Chief Executive Officer Erez Raphael said 2025…
DarioHealth Corp. (DRIO) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DRIO.
U.S. House Trading
No House trades found for DRIO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.